These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36638330)

  • 1. Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
    Horn DM; Alpert AE; Duggan MG; Garcia NA; Jacobson M
    JCO Oncol Pract; 2023 Apr; 19(4):e476-e483. PubMed ID: 36638330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share.
    Chen AJ; Kaiser KM; Gascue L; Manetas MA; Van Nuys K
    Health Aff (Millwood); 2023 Jun; 42(6):779-784. PubMed ID: 37276475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
    Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
    JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 7. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
    Cesarec A; Likić R
    Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
.
    Mengato D; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):160-162. PubMed ID: 30574866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar underutilization alone does not foretell a broken biologics market.
    LaMountain F; Beinfeld MT; Wong W; Kim E; Chambers JD
    Health Aff Sch; 2024 Jul; 2(7):qxae090. PubMed ID: 39071106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
    Esteva FJ; Saeki T; Kim H; Stebbing J
    Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
    Chen HH; Yemeke T; Ozawa S
    PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial Validates Biosimilar for Trastuzumab.
    Cancer Discov; 2016 Jul; 6(7):686-7. PubMed ID: 27277256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease.
    Beinfeld MT; LaMountain F; Wong W; Kim E; Chambers JD
    Health Aff (Millwood); 2024 Sep; 43(9):1290-1295. PubMed ID: 39226499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.
    Wu Q; Wang Z; Fu Y; Luo R; Sun J
    Glob Health Res Policy; 2024 Oct; 9(1):42. PubMed ID: 39367503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
    Liu T; Liu D; Jin Y; Dong M
    Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer.
    Leung JH; Tai YS; Wang SY; Yip Fion HT; Tsung-Chin H; Chan AL
    Breast; 2022 Oct; 65():91-97. PubMed ID: 35870421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.